OJJAARA study results

Study 1: OJJAARA was studied in adults with MF symptoms* and anemia (Hb <10 g/dL) compared to danazol

Study 1 included 195 people with MF symptoms and anemia who had taken a JAK inhibitor before
Study 1 included 195 people with MF symptoms and anemia who had taken a JAK inhibitor before

Hb=hemoglobin; JAK=Janus kinase.
*MF symptoms included night sweats, pain under ribs on left side, itching, fullness, abdominal discomfort, bone pain, and fatigue.

Primary results

The primary goal of Study 1 was to compare the percentage of people treated with OJJAARA or danazol who were able to reduce their overall MF symptom score by 50% or more from the beginning of the study to Week 24.

Reduced MF-related symptoms
Reduced MF-related symptoms

MF symptom score was reduced by 50% or more in:

  • 25% (32 out of 130) of people taking OJJAARA 
  • 9% (6 out of 65) of people taking danazol 

Secondary results

A secondary goal of the study was to compare the percentage of people treated with OJJAARA or danazol who were able to reduce their spleen size by 35% or more from the beginning of the study to Week 24. Another secondary goal was to see if the percentage of people who were transfusion independent between Weeks 12 and 24 was similar for people taking OJJAARA versus danazol.

Reduced spleen size
Reduced spleen size

Spleen size was reduced by 35% or more in:

  • 22% (29 out of 130) of people taking OJJAARA 
  • 3% (2 out of 65) of people taking danazol
Transfusion independence
Transfusion independence

A similar percentage of people were transfusion independent between Weeks 12 and 24 in the two groups. This was seen in:

  • 30% (39 out of 130) of people taking OJJAARA 
  • 20% (13 out of 65) of people taking danazol

The symptom score was measured using a form that tracked MF symptoms like fatigue, night sweats, bone pain, and others during treatment.
No transfusion or Hb <8 g/dL.

Divider with icon
Divider with icon

Study 2: OJJAARA was compared to ruxolitinib in a study of 432 adults with MF who had never taken a JAK inhibitor before

Study 2 included a subset, or smaller group of 181 people with anemia (Hb<10 g/dL)
Study 2 included a subset, or smaller group of 181 people with anemia (Hb<10 g/dL)

Spleen size results

A goal of this study was to see if OJJAARA was similar to ruxolitinib in reducing spleen size in people with MF who have anemia. This means that a similar percentage of people in both groups would see a reduction in spleen size of 35% or more at Week 24 compared to the start of the study.

Similar spleen size reduction
Similar spleen size reduction

Spleen size was reduced by 35% or more in:

  • 31% (27 out of 86) of people with anemia taking OJJAARA 
  • 33% (31 out of 95) of people with anemia taking ruxolitinib

OJJAARA safety profile

What are the possible side effects of OJJAARA?

SEE OJJAARA SIDE EFFECTS